Definium Therapeutics (DFTX) Equity Average (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Equity Average data on file, last reported at $305.6 million in Q1 2026.

• Quarterly Equity Average rose 31.65% year-over-year to $305.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $305.6 million (up 31.65% YoY) and the FY2025 annual result came in at $286.9 million, up 79.54% from the prior year.
• Equity Average improved to $305.6 million in Q1 2026 per DFTX's latest filing, from $231.5 million in the prior quarter.
• Across five years, Equity Average topped out at $305.6 million in Q1 2026 and bottomed at $87.1 million in Q4 2023.
• The 5-year median for Equity Average is $152.3 million (2022), against an average of $174.4 million.
• The widest annual swing landed in 2023, when Equity Average plunged 42.82%; it then soared 189.26% in 2024.
• Tracing DFTX's Equity Average over 5 years: stood at $152.3 million in 2022, then tumbled by 42.82% to $87.1 million in 2023, then jumped by 189.26% to $251.8 million in 2024, then dropped by 8.08% to $231.5 million in 2025, then jumped by 32.03% to $305.6 million in 2026.
• Per Business Quant, the three latest DFTX Equity Average figures stand at $305.6 million (Q1 2026), $231.5 million (Q4 2025), and $158.0 million (Q3 2025).

Peer Comparison